摘要
目的:探讨紫杉醇联合顺铂一线治疗晚期食管癌的疗效及安全性。方法:回顾性分析2008年1月至2013年6月我院收治的以紫杉醇联合顺铂作为一线化疗方案的晚期食管癌患者的临床及病理资料,根据上述纳入患者的性别、年龄、肿瘤位置、肿瘤分化程度、肿瘤进展情况等一般资料,按1∶1的比例选取同期以多西他赛联合顺铂作为一线化疗方案的晚期食管癌患者进行配对。比较病例组(紫杉醇联合顺铂)和对照组(多西他赛联合顺铂)一线化疗不良反应发生情况及生存情况的差异。结果:病例组因食管癌及其相关疾病死亡26例,存活14例,一线化疗后进展27例。PFS 3~30.5个月,中位PFS 10.7个月。OS 2~31个月,中位OS 13个月。对照组因食管癌及其相关疾病死亡25例,存活15例,一线化疗后进展30例。PFS 2.9~47个月,中位PFS 12个月。OS 1~49个月,中位OS 10个月。两组患者PFS及OS的差异,具有统计学意义(P<0.05)。单因素和多因素分析显示,除临床分期和初治时远处转移器官数目外,一线化疗方案中紫杉醇联合顺铂与否也是影响两组患者PFS和OS的独立预后因素。结论:与多西他赛联合顺铂相比,紫杉醇联合顺铂一线治疗晚期食管癌的疗效显著,对于进展期食管癌患者来说是一个可供选择的一线治疗方案。
Objective： To compare the clinical outcomes of first-line chemotherapy with paclitaxel plus cisplatinum versus docetaxel plus cisplatinum in patients with locally advanced or metastatic esophagus cancer. Methods： The incidence of side effects and survival of the first-line chemotherapy were compared between paclitaxel plus cisplatin and control group（ docetaxel plus cisplatin）. Results： The difference of PFS and OS between the two groups were statistically significant（ P〈 0. 05）. Conclusion： Compared with docetaxel combined with cisplatin,paclitaxel combined with cisplatin is a first-line therapy for advanced esophageal cancer,which was an alternative first-line treatment for advanced esophageal cancer patients.
出处
《现代肿瘤医学》
CAS
2017年第15期2405-2409,共5页
Journal of Modern Oncology
关键词
食管癌
紫杉醇
多西他赛
顺铂
化疗
esophageal cancer
paclitaxel
docetaxel
cisplatin
chemotherapy
